Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

Posted: August 14, 2022 at 2:33 am

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -

Original post:
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

Related Posts